Key Capital partners and supports business initiatives with the potential to make a difference to our Health, Wealth, or Environment.
Ticker Symbol: KCPC
Exchange: OTC Pink
Signature Stock Transfer Inc.
2632 Coachlight Ct.
Plano, TX, 75093
972-612-4120
signaturestocktransfer@msn.com
Peter Boonen, Chairman
Peter Boonen, Chairman
GET
In Touch
NEW YORK, NY, January 28, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that as SARS-CoV-2 continues to spread, and reports of increases in daily infections, hospitalizations, and deaths are becoming regular, Key Capital plans to market its Immunitor partnered potentially therapeutic oral pill as a supplement commencing early February.
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
(Precision Vaccinations)
New York-based Key Capital Corporation announced independent laboratory testing of its partnered Immunitor COVID-19 patented oral pill vaccine in an ongoing university study is providing promising early support for the safety and efficacy of the vaccine.
